Start­up mak­ing Cas9 proxy for gene edit­ing gets $55M to de­vel­op tools/soft­ware

Boul­der-based start­up In­scrip­ta — which you might re­mem­ber as the com­pa­ny that dis­cov­ered a new CRISPR en­zyme… and then gave it away for free — just land­ed $55.5 mil­lion in a Se­ries C round.

In­scrip­ta made head­lines last De­cem­ber when it an­nounced the com­pa­ny had un­earthed what its call­ing “MAD7,” an al­ter­na­tive en­zyme to CAS9 that could be used to ed­it DNA. Hav­ing a proxy for Cas9 can get more com­pa­nies jump­ing in­to the gene edit­ing game, In­scrip­ta’s CEO Kevin Ness tells me.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.